Cardiac Dimensions raises $35.5M in venture capital

TriMed Staff | | Health Imaging | Screening
Cardiac Dimensions has closed $35.5 million in new venture capital.

Johnson & Johnson Development and Lumira Capital co-led the financing, along with Mitsubishi UFJ Capital, West River Capital and Montgomery. Existing investors Frazier Healthcare Ventures, Interwest Partners, MPM Capital and Polaris Venture Partners also participated. Montgomery served as the exclusive private placement agent on the financing.

The Kirkland, Wash.-Cardiac Dimensions said the funds will be used to execute clinical trials in the United States and Europe supporting the Carillon Mitral Contour System. The Carillon system is a percutaneous treatment of functional mitral regurgitation, and is currently under evaluation in pilot studies in Europe, South America, and Australia.

TriMed Staff

Related Content

Routine abdominal CTs offer insight into cardiovascular risk
Screening efforts have helped avert millions of cancer-related deaths in recent decades
What breast density status can tell us about cardiovascular risk
FDA clears AI tool that flags signs of heart disease in chest CT scans
Patients without PCPs struggle to access lung cancer screening, despite eligibility
Breast cancer rates among women in their 30s are on the rise

Around the web

Cardiovascular Business
New AI program delivers rapid, accurate echo video assessments

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Radiology Business
Key Medicare reimbursement and No Surprises Act updates from RSNA 2024

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

Cardiovascular Business
Philips, Mayo Clinic using AI to improve cardiac MRI technology

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.